What is Plasticell?
Founded in 2002 and headquartered in Stevenage, United Kingdom, Plasticell is at the forefront of developing novel therapies by leveraging award-winning combinatorial screening technology. The company's expertise lies in the precise manipulation of stem cells and more differentiated cell types, positioning it as a key player in the regenerative medicine and cell therapy sectors. Its proprietary technology enables rapid identification and optimization of cell-based treatments, addressing unmet medical needs across various disease areas.
How much funding has Plasticell raised?
Plasticell has raised a total of $2.7M across 2 funding rounds:
Other Financing Round
$774K
Private Equity
$1.9M
Other Financing Round (2007): $774K with participation from Innovate UK and Department of Trade & Industry
Private Equity (2021): $1.9M, investors not publicly disclosed
Key Investors in Plasticell
Innovate UK
Innovate UK is an innovation agency that supports business growth and technological advancement, likely focusing on high-potential UK-based companies in sectors like biotechnology.
Department of Trade & Industry
The Department of Trade and Industry, historically involved in supporting industrial and economic development, likely provided backing to Plasticell to foster innovation and growth within the UK's biotechnology sector.
What's next for Plasticell?
The substantial enterprise-level funding indicates Plasticell is poised for significant scaling and advancement of its therapeutic pipeline. This strategic investment will likely fuel further research and development, clinical trial progression, and potential commercialization efforts. The company's focus on innovative cell manipulation technologies suggests a trajectory towards becoming a leader in the biotech industry, with future growth potentially involving strategic partnerships or expanded market reach.
See full Plasticell company page
